AUR-AEPZ-TTM1-A-1-1-R-A742-41
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R247 | — | — | 0.888 |
| 2 | TCGA-ZF-A9R5-01A-12R-A42T-07 | — | — | 0.873 |
| 3 | SRR975556 | — | — | 0.873 |
| 4 | SRR35579813 | — | B | 0.868 |
| 5 | 42371f73-e570-4ec7-ac5d-b4718183c1e8 | — | — | 0.860 |
| 6 | TCGA-BH-A0HN-01A-11R-A10U-07 | — | B | 0.854 |
| 7 | TCGA-CF-A5U8-01A-11R-A28M-07 | — | — | 0.851 |
| 8 | SRR2016961 | — | — | 0.847 |
| 9 | TCGA-AO-A12H-01A-11R-A115-07 | — | B | 0.842 |
| 10 | 308a5759-8930-433f-8d11-4c3da6ed0e29 | — | — | 0.841 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 9 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.240 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.180 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.160 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.060 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |